Imunon
NASDAQ: IMNNLawrenceville, US · Delaware corporation
Find your way into Imunon
91 people in our graph share verified history with the Imunon team — schools, employers, funds. One of them is your warm intro.
Ben Davisunlockedknows Stacy Lindborg · together at Baylor University (overlapped)
×9knows the team · via Baylor University
×2knows the team · via Rutgers University–Newark
Imunon develops DNA-based immunology technologies designed to treat difficult-to-treat conditions including ovarian cancer and infectious diseases. The company's platforms instruct the immune system to generate targeted therapeutic responses.
Founders & leadership
DG
David GaieroExecutive
MT
Michael TardugnoinExecutive Chairman
KA
Khursheed AnwerExecutive
SL
Stacy LindborginPresident & Chief Executive Officer, Board DirectorStacy Lindborg brings nearly three decades of experience in pharmaceutical and biotechnology operations, including roles in general management, research and development, strategy, and analytics across US and international markets. She has held executive positions focused on operational transformation and organizational development within regulated life sciences environments.
NB
Nicholas BorysinChief Medical Officer2007–2023Nicholas Borys leads development at Imunon, where he previously worked on gene therapy treatments for ovarian cancer and other solid tumors. He has extensive experience designing and managing clinical trials from Phase 1 to Phase 3 across multiple regions and modalities, including radiopharmaceuticals, nanotechnologies, and cell-based therapies.
SR
Stacy R. LindborginPresident & Chief Executive Officer, Board DirectorStacy R. Lindborg is CEO and President of Imunon. She has spent nearly three decades in general management, R&D, and strategy roles across pharmaceutical and biotechnology companies, with expertise in analytics, operational transformation, and regulatory compliance.
JC
Jeffrey ChurchChief Financial Officer
DF
Douglas FallerinChief Medical OfficerDouglas Faller is Chief Medical Officer of Imunon, which develops DNA-based immunology technologies for cancer and infectious disease treatment. He is a Boston-based physician-scientist with over 20 years of pharmaceutical and biotech experience in drug discovery and clinical development across oncology, hematology, immunology, and neurology, alongside over 25 years of academic research in drug discovery, cell and molecular biology, and team leadership.
Board
FF
Frederick FritzBoard director
DB
Donald BraunBoard director
JD
James DentzerBoard director
CP
Christine PellizzariBoard director
Funding
SEC filings, press & company announcements$36.8M disclosed across 5 rounds · 2014–2026
- $10MraisedJun 2026 · 2 sourcesSource ↗
▶$3.3MraisedMay 2025 · 3 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David GaieroExecutive Officer
- James E. DentzerDirector
- Donald P. BraunDirector
- Michael H. TardugnoExecutive Officer, Director
- Frederick J. FritzDirector
- Stacy R. LindborgExecutive Officer, Director
- Christine PellizzariDirector
- Douglas FallerExecutive Officer
- Susan EylwardExecutive Officer
- Khursheed AnwerExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $227.5K
- Placement agents
- Brookline Capital Markets, a division of Arcadia Securities, LLC, H.C. Wainwright & Co., LLC
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2024 · 4 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick FritzDirector
- Donald BraunDirector
- David GaieroExecutive Officer
- James DentzerDirector
- Michael TardugnoExecutive Officer
- Khursheed AnwerExecutive Officer
- Christine PellizzariDirector
- Stacy LindborgExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- H.C. Wainwright & Co., LLC, Brookline Capital Markets
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJun 2015 · 3 investors · PharmaceuticalsRule 506(b)
▶$5.1MraisedJun 2015 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick J. FritzDirector
- Khursheed AnwerExecutive Officer
- Alberto MartinezDirector
- Augustine ChowDirector
- Robert W. HooperDirector
- Michael H. TardugnoExecutive Officer, Director
- Nicholas BorysExecutive Officer
- Jeffrey W. ChurchExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Finders' fees
- $561.8K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedJun 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$8.5MraisedJun 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas BorysExecutive Officer
- Robert W. HooperDirector
- Michael H. TardugnoExecutive Officer, Director
- Augustine ChowDirector
- Frederick J. FritzDirector
- Jeffrey W. ChurchExecutive Officer
- Khursheed AnwerExecutive Officer
- Alberto MartinezDirector
- Max E. LinkDirector
- Offering amount
- $8.5M
- Amount sold
- $8.5M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$10.6Mvaluation at IPOFeb 2017 · $0.22/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlapRegeneron NASDAQ: REGN www.regeneron.com31 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Robinhood27 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Imunon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Imunon flags going concern risk in Q2 2026 | IMNN Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Imunon do?
- Imunon develops DNA-based immunology technologies designed to treat difficult-to-treat conditions including ovarian cancer and infectious diseases. The company's platforms instruct the immune system to generate targeted therapeutic responses.
- How much funding has Imunon raised?
- Imunon has disclosed $36.8M raised across 5 rounds.
- Where is Imunon headquartered?
- Imunon is headquartered in Lawrenceville, US.